ANNUAL REPORT - Department of Biotechnology

13. Recombinant formulated composition(s) M/s. Avestha Gengrain, Bangalore
of the novel erythropoiesis stimulating
protein
14. Recombinant IN-105 M/s. Biocon India Ltd., Bangalore
15. Recombinant human Nesiritide M/s. USV Ltd., Mumbai
16. rh-Epoetin alpha M/s. Cadila Healthcare Ltd., Ahmedabad
17. r-monoclonal tetanus immunoglobulin M/s. Bharat Serum and Vaccines Ltd,
Mumbai
18. Recombinant Insulin Glargine M/s. Biocon India Ltd., Bangalore
19. rh-G-CSF M/s. Reliance Life Sciences Ltd, Mumbai
20. rh-polysialated G-CSF M/s. Serum Institute of India Ltd, Pune
21. Peg-rh-G-CSF M/s. Cadila Healthcare Ltd., Ahmedabad
22. Recombinant G-CSF M/s. Shantha Biotechnics Pvt. Ltd., Hyderabad
23. Bevacizumab M/s Dr Reddy's Laboratories, Hyderabad
24. Trastuzumab M/s Dr Reddy's Laboratories, Hyderabad
The workshops, seminars and symposia organized
by the Department of Biotechnology on biosafety
rules and regulations have increased the awareness
among the research institutions working in the area
of r-DNA technology. At present there are 358 IBSCs
constituted at various public-funded institutions,
universities, private R&D institutions and industries.
157
RCGM felt that suitable guidelines have to be
developed while developing transgenics / varieties.
In order to harmonize the existing guidelines on
biosafety issues and to develop specific guidelines
while evaluating transgenics for biotic and abiotic
stress response, herbicide tolerance, containment
facility in polyhouses etc. a sub-committee
comprising RCGM members is being constituted
Bioprocess and Product Development